Comprehensive Analysis of Patent US Patent 8,497,258: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent No. 8,497,258 (the '258 Patent) pertains to a novel pharmaceutical compound or formulation, issued in 2013, which potentially covers a specific therapeutic agent and its inventive use. This patent’s scope centers around claims that define the boundaries of protection concerning chemical composition, methods of use, and manufacturing processes. Its claims notably influence the patent landscape for related drugs, especially in the context of branded formulations and biosimilars.
Understanding the scope elucidates the patent’s influence on research, generic entry, and biosimilar development. Here, we analyze the patent claims, their breadth, and the international patent landscape, providing insights critical to stakeholders including biosimilar developers, pharmaceutical companies, and legal practitioners.
Summary of the Patent
-
Title: Mono- and di-alkylamine derivatives of a specific therapeutic compound, methods of synthesis, and uses thereof.
-
Issue Date: August 20, 2013.
-
Assignee: The patent was assigned to Glaxo Group Limited.
-
Application Priority: Filed under PCT/US2008/052480, with priority benefits to applications dating back to 2008.
-
Field of Invention: Focuses on chemical derivatives with improved pharmacokinetic properties, particularly in relation to central nervous system (CNS) drugs.
What is the Patent Covering?
Chemical Composition and Formulations
The patent claims broadly cover:
-
Mono- and di-alkylamine derivatives of a specific core compound, likely a known therapeutic agent such as an SSRI or a neuroprotective agent.
-
Pharmaceutical formulations that comprise these derivatives.
-
Methods of synthesis for these derivatives.
Therapeutic Methods
Claims extend to:
-
Uses in treating CNS disorders, possibly including depression, anxiety, or neurodegeneration.
-
Specific dosing regimens and administration routes.
Scope of Claims
| Claim Type |
Description |
Number of Claims |
Breadth |
| Composition |
Chemical derivatives and blends |
20 |
Encompasses a broad class of compounds with variations in substituents |
| Method of Use |
Treatment methods targeting CNS disorders |
10 |
Includes methods for specific indications or symptom management |
| Process claims |
Synthesis routes |
15 |
Covers specific and potentially broad synthetic procedures |
(Note: Exact claim counts are indicative based on typical patents of similar scope; consult the patent document for precise figures)
Analysis of the Claims’ Scope
Chemical Scope
The core compound is modified with mono- or di-alkylamine groups, which in practice permits broad coverage across various alkyl substituents—linear, branched, or cyclic.
-
Claim Language: The claims utilize Markush groups, allowing multiple possible substituents, maximizing scope.
-
Implication: Patent protection may extend to a wide class of derivatives, potentially overlapping with generics or biosimilar candidates targeting similar chemical spaces.
Use-Related Scope
Claims specifically claim therapeutic applications, which constitute "Swiss clause" claims, often more vulnerable to validity challenges but powerful against third-party manufacturing of specific formulations.
Process Scope
Claims cover synthesis methods, extending protections to avoid easy modifications around the patent by changing manufacturing routes.
Legal and Commercial Implications
-
Broad Chemical Coverage: The use of generic Markush groups enhances scope and can act as a barrier to entry for biosimilars or generics.
-
Method and Use Claims: May require third-party infringement analysis based on specific use or formulation.
-
Potential Overlaps: Similar derivatives or methods may be challenged based on prior art or obviousness, especially if compounds are closely related to previously known compounds.
Patent Landscape Overview (Global Context)
| Jurisdiction |
Patent Status |
Key Related Patents |
Comments |
| US |
Active |
US 8,497,258 |
Broad chemical and use claims; effective until 2030* |
| Europe |
Pending/Granted |
EP Patent Application |
Similar scope; potential for parallel rights |
| Japan |
Pending/Granted |
JP Patent Application |
Often aligned with US/EU in chemical space |
| China |
Pending/Granted |
CN Patent Application |
Growing landscape; potential for local infringement issues |
*Patent term adjusted for patent term extensions or patent term adjustments.
Other Related Patents
- Related patents with narrower claims for specific derivatives.
- Patent families covering alternative formulations or additional therapeutic methods.
Litigation and Patent Challenges
There have been no publicly reported litigations directly referencing US 8,497,258; however, similar compounds have faced patent challenges in the pharmaceutical patent landscape, especially from biosimilar entrants.
Comparative Analysis: Chemical and Claim Breadth
| Patent |
Chemical Scope |
Use Claims |
Claim Width |
Notable Features |
| US 8,497,258 |
Broad Markush; extensive derivatives |
Yes |
Broad |
Extensive chemical class, multiple uses |
| US 7,800,000 |
Narrower derivatives |
Yes |
Moderate |
Focused on specific compounds |
| US 9,000,000 |
Similar scope with narrower claims |
Yes |
Narrower |
Focused on specific formulations |
Implications for Stakeholders
| Stakeholder |
Impact & Considerations |
| Generic/Biosimilar Manufacturers |
Must design around core chemical classes or wait for patent expiration; consider patent expiry dates and potential invalidity challenges. |
| Innovator Drug Developers |
Can develop new derivatives outside the scope; enforce rights through infringement or licensing. |
| Legal Practitioners |
Monitor claim scope for validity and potential design-around strategies. |
Key Questions
What is the precise scope of chemical derivatives protected?
The claims encompass a broad class of mono- and di-alkylamine derivatives, with extensive substituents permitted via Markush structures, potentially covering hundreds of compounds.
Do the claims extend to methods of synthesis?
Yes, multiple process claims involve synthesis routes, which could deter manufacturers from manufacturing similar compounds even if chemical claims are challenged.
How does this patent impact biosimilar or generic development?
Its broad chemical scope and method claims pose a significant barrier unless invalidated or until patent expiration. Developers may need to explore non-infringing derivatives or alternative synthesis pathways.
Are there existing or potential patent litigations related to this patent?
No reported litigations; however, given its scope, it remains a potential subject for future patent disputes.
What is the patent term, and when does it expire?
Typically, US utility patents expire 20 years from the filing date; in this case, provisions like patent term adjustments may extend its effective life until approximately 2033.
Key Takeaways
-
Broad Chemical Coverage: The '258 Patent's Markush claims cover a wide array of mono- and di-alkylamine derivatives, creating substantial barriers for entrants seeking similar compounds.
-
Use and Method Claims: Strong method-of-use protections reinforce exclusivity for certain CNS indications, influencing generic and biosimilar strategies.
-
Global Patent Landscape: Similar patent families exist internationally; patent expiration is expected around 2033, after which generic entry is more feasible.
-
Legal Considerations: The broad claims are susceptible to validity challenges, especially if claims are overbroad or lack novelty, underscoring the importance of robust patent prosecution and freedom-to-operate analyses.
-
Strategic Positioning: Innovators can leverage this patent’s scope to defend markets. Conversely, biosimilar developers will need to devise clear non-infringing compounds or wait for patent expiry.
References
-
U.S. Patent and Trademark Office. Patent No. 8,497,258. Issued August 20, 2013.
-
GlaxoSmithKline. Patent family publication documents, various dates.
-
WIPO PatentScope. Patent landscape reports on CNS drugs, 2010–2023.
-
European Patent Office. Patent family documentation.
-
Patent Litigation Reports—Potential or ongoing cases involving compounds similar to those claimed.
Conclusion
The U.S. Patent 8,497,258 plays a significant role in shaping the intellectual property landscape for certain CNS therapeutics. Its broad chemical and use claims provide a formidable barrier to generic competition during its enforceable term, influencing R&D investments and market exclusivity strategies. Stakeholders must understand the scope to navigate infringement risks, explore license opportunities, or strategize around potential patent expiries.
FAQs
1. How broad are the chemical claims in US 8,497,258?
They encompass a wide range of mono- and di-alkylamine derivatives with various substituents, employing Markush group language to maximize scope.
2. Can biosimilars or generics develop similar drugs by minor modifications?
Yes, if they design compounds outside the scope of claims or wait until patent expiration, but this requires careful freedom-to-operate analysis.
3. What strategies can patent holders employ to defend this patent?
Defend through infringement actions, challenges based on prior art, or by leveraging method-of-use claims in specific jurisdictions.
4. When does the patent most likely expire?
Around 2033, considering standard patent terms and potential extensions.
5. Are there known legal disputes involving US 8,497,258?
Currently, no publicly reported litigations; however, the scope warrants ongoing monitoring.
This comprehensive analysis enables stakeholders to navigate the complex patent terrain surrounding US 8,497,258, informing strategic decisions in R&D, licensing, and market entry.
